Example of a novel DPI device developed by Team members (modified from WO/2004/110536)
In order to achieve respiratory deposition, dry powder drug particles need to be less than 5 microns in diameter. Particles of this size range are inherently difficult to aerosolise due to the high adhesive and cohesive forces and have to be formulated with larger carriers or as complex multi-particulate systems. The Respiratory Technology Team at the Institute focus on developing new and innovative devices that enhance powder dispersion and aerosol efficiency. We use a combination of computational and rapid prototyping techniques to design new inhalers (or assess the efficiency of current devices) and test these in our purpose built laboratories. We have developed a series of approaches focussed on drug and formulation specific segregation mechanisms that ultimately will have health care benefits for a wide range of diseases.
Additionally, the Team works with the clinical management group at the Institute, to study patient usability and compliance. We develop new approaches to ensure ease of use and promote patient education within this area of medical science.